Publications

Vaccine trust and the limits of information.

LARSON, HJ;

2016

Science (New York, NY), (2016).353 6305 10.1126/science.aah6190.

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).

Henao-Restrepo, AM; CAMACHO, A; Longini, IM; WATSON, CH; EDMUNDS, WJ; Egger, M; Carroll, MW; Dean, NE; Diatta, I; Doumbia, M; Draguez, B; Duraffour, S; Enwere, G; Grais, R; Gunther, S; Gsell, P-S; Hossmann, S; Watle, SV; Kondé, MK; Kéïta, S; Kone, S; Kuisma, E; Levine, MM; Mandal, S; Mauget, T; ... Kieny, M-P.

2016

Lancet, (2016).389 10068 10.1016/S0140-6736(16)32621-6.

Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?.

JIT, M; Hutubessy, R;

2016

Applied health economics and health policy, (2016).14 3 10.1007/s40258-016-0224-7.

Generation of virus-like particles for emerging epizootic haemorrhagic disease virus: Towards the development of safe vaccine candidates.

ALSHAIKHAHMED, K; ROY, P;

2016

Vaccine, (2016).34 8 10.1016/j.vaccine.2015.12.069.

The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey.

LARSON, HJ; DE FIGUEIREDO, A; Xiahong, Z; SCHULZ, WS; Verger, P; Johnston, IG; Cook, AR; Jones, NS;

2016

EBioMedicine, (2016).12, 10.1016/j.ebiom.2016.08.042.

Influenza Vaccination Generates Cytokine-Induced Memory-like NK Cells: Impact of Human Cytomegalovirus Infection.

GOODIER, MR; Rodriguez-Galan, A; Lusa, C; Nielsen, CM; Darboe, A; Moldoveanu, AL; White, MJ; BEHRENS, R; RILEY, EM;

2016

Journal of immunology (Baltimore, Md, (2016).197 1 10.4049/jimmunol.1502049.

Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men.

Lin, A; Ong, KJ; Hobbelen, P; King, E; Mesher, D; EDMUNDS, WJ; Sonnenberg, P; Gilson, R; Bains, I; Choi, YH; TANTON, C; Soldan, K; JIT, M;

2016

Clinical infectious diseases, (2016).64 5 10.1093/cid/ciw845.

Feasibility and acceptability of delivering adolescent health interventions alongside HPV vaccination in Tanzania.

WATSON-JONES, D; LEES, S; Mwanga, J; Neke, N; Changalucha, J; Broutet, N; Maduhu, I; KAPIGA, S; Chandra-Mouli, V; Bloem, P; ROSS, DA;

2016

Health policy and planning, (2016).31 6 10.1093/heapol/czv119.

Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges.

Vandebosch, A; Mogg, R; Goeyvaerts, N; Truyers, C; GREENWOOD, B; WATSON-JONES, D; Herrera-Taracena, G; Parys, W; Vangeneugden, T;

2016

Clinical trials (London, England), (2016).13 1 10.1177/1740774515621059.

Is It Time for Vaccination to "Go Viral"?.

Philip, RK; Shapiro, M; PATERSON, P; Glismann, S; Van Damme, P;

2016

The Pediatric infectious disease journal, (2016).35 12 10.1097/INF.0000000000001321.